Cyteir Therapeutics, Inc.
CYT · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $129 | $134 | $137 | $147 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | -$0 | -$0 | -$0 | $0 |
| Other Curr. Assets | $1 | $0 | $1 | $2 |
| Total Curr. Assets | $131 | $134 | $138 | $149 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $2 |
| Total NC Assets | $0 | $0 | $1 | $4 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $131 | $134 | $139 | $153 |
| Liabilities | – | – | – | – |
| Payables | $1 | $1 | $1 | $1 |
| Short-Term Debt | $0 | $0 | $0 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | -$0 | -$0 | $0 | $0 |
| Other Curr. Liab. | $5 | $5 | $3 | $3 |
| Total Curr. Liab. | $6 | $7 | $4 | $5 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $2 |
| Total NC Liab. | $0 | $0 | $0 | $2 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $6 | $7 | $4 | $7 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$163 | -$159 | -$151 | -$138 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $288 | $287 | $286 | $284 |
| Total Equity | $125 | $128 | $135 | $146 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $131 | $134 | $139 | $153 |
| Net Debt | -$129 | -$134 | -$137 | -$146 |